NCT02485769View on ClinicalTrials.gov

Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects

PHASE1CompletedINTERVENTIONAL
Enrollment

71

Participants

Timeline

Start Date

June 30, 2015

Primary Completion Date

April 30, 2016

Study Completion Date

April 30, 2016

Conditions
Healthy
Interventions
DRUG

PF-06650833

Suspension

DRUG

Placebo

Suspension

DRUG

PF-06650833

Tablet (Modified Release)

DRUG

Placebo

Tablet (Modified Release)

Trial Locations (1)

06511

Pfizer New Haven Clinical Research Unit, New Haven

Sponsors

Lead Sponsor

Pfizer
All Listed Sponsors
lead

Pfizer

INDUSTRY

NCT02485769 - Study To Evaluate The Safety, Tolerability, And Pharmacokinetics Of Oral Pf-06650833 In Healthy Subjects | Biotech Hunter | Biotech Hunter